Evidence map›Paper›PMID 41012606›Full record

ArticleViruses2025

APOBEC3B Promotes SARS-CoV-2 Through Activation of PKR/eIF2⍺ and AMPD2 Dysregulation.

Benjamin Fixman, Lavanya Manjunath, Philip Sell, Shanshan Wang, Tamara Margaryan, Connor Qiu, Hanjing Yang, Rémi Buisson, Xiaojiang S Chen

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Benjamin FixmanMolecular and Computational Biology, Department of Biological Sciences, University of Southern, Los Angeles, CA 90089, USA.ORCID 0000-0002-7592-3761
Lavanya ManjunathDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, USA.ORCID 0000-0003-1898-3570
Philip SellDepartment of Molecular Microbiology and Immunology, The Hastings and Wright Laboratories, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0009-0009-8636-5628
Shanshan WangMolecular and Computational Biology, Department of Biological Sciences, University of Southern, Los Angeles, CA 90089, USA.
Tamara MargaryanMolecular and Computational Biology, Department of Biological Sciences, University of Southern, Los Angeles, CA 90089, USA.
Connor QiuMolecular and Computational Biology, Department of Biological Sciences, University of Southern, Los Angeles, CA 90089, USA.ORCID 0009-0008-5276-5933
Hanjing YangMolecular and Computational Biology, Department of Biological Sciences, University of Southern, Los Angeles, CA 90089, USA.ORCID 0000-0001-7187-3720
Rémi BuissonDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, USA.ORCID 0000-0002-7196-8209
Xiaojiang S ChenMolecular and Computational Biology, Department of Biological Sciences, University of Southern, Los Angeles, CA 90089, USA.

Funding

Structural Basis of APOBEC Functions and Interactions with HIV-VifR01AI150524 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI XIAOJIANG S CHEN · 2019 to 2026
$3.8M
Molecular Mechanisms of APOBEC-Induced Mutagenesis in CancerR37CA252081 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Remi Buisson · 2021 to 2026
$2.5M
NF-KB regulation by the DNA damage responseR21ES036190 · NIEHS · UNIVERSITY OF CALIFORNIA-IRVINE · PI BUISSON, REMI · 2025 to 2025
$432k
Role of APOBEC3B in the Innate Immune ResponseR21AI185033 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Remi Buisson · 2025 to 2026
$425k
NCI NIH HHS R37 CA252081NIAID NIH HHS R01 AI150524NIAID NIH HHS R21 AI185033NIEHS NIH HHS R21 ES036190NIH HHS 5R01AI150524-13
6 · The paper itself

Abstract

APOBEC3B (A3B) has been implicated in host-virus interactions, but its role in SARS-CoV-2 infection is unclear. Here, we demonstrate that A3B is overexpressed in bronchoalveolar lavage fluid (BALF) cells from severe COVID-19 patients compared to those with mild disease. A3B knockdown in Caco-2 cells significantly reduces SARS-CoV-2 infectivity, likely through attenuation of the PKR-mediated integrated stress response, a pathway proposed to promote SARS-CoV-2. Single-cell RNA sequencing (scRNA-seq) data suggest that BALF cells from severe COVID-19 patients exhibit a repressed state for cellular translation, potentially mediated by eIF2α phosphorylation. However, in A549-ACE2 cells, SARS-CoV-2 does not activate PKR, but A3B knockdown still reduces SARS-CoV-2 infectivity, suggesting an alternative mechanism of action in different cellular contexts. To further investigate A3B's role in severe COVID-19, we employed Geneformer, a transformer-based machine learning model, which predicted that A3B knockout would perturb AMPD2 (adenosine monophosphate deaminase 2), a key enzyme in purine metabolism and immune regulation. We validated this prediction using bulk RNA-seq and clinical scRNA-seq data, confirming that AMPD2 expression is downregulated in severe COVID-19 but restored upon A3B knockdown. Together, these findings suggest that A3B plays a proviral role in SARS-CoV-2 infection by modulating translational control and immune regulatory networks, warranting further studies to elucidate the underlying mechanistic details.

Indexed as

COVID-19Cytidine DeaminaseeIF-2 KinaseEukaryotic Initiation Factor-2SARS-CoV-2A549 CellsCaco-2 CellsHost-Pathogen InteractionsHumansMinor Histocompatibility AntigensAPOBEC3B protein, humanCytidine DeaminaseEIF2AK2 protein, humaneIF-2 KinaseEukaryotic Initiation Factor-2Minor Histocompatibility AntigensAMPD2APOBEC3B (A3B)Geneformerimmune regulatory networksPKR-mediated integrated stress responseProviral roleSARS-CoV-2 infectivitysevere COVID-19

Identifiers

PMID41012606
PMCPMC12474056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.